
<!DOCTYPE html>
<html lang="en">
    <ceneter>
<head>
    <meta charset="UTF-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Document</title>
    <link rel="stylesheet" ; href="i.css">
</head>
<body class="vi">
    <center>
        <div class="i">
            <a href="home.html">
            <button class="o" style="padding: 20px;">Home</button></a><a href="aboutcovid.html"> <button class="p" style="padding: 20px;">About Covid</button></a> <a href="vaccine.html"><button class="f" style="padding: 20px;">Vaccine</button></a> <a href="new disease.html"><button class="a" style="padding: 20px;"> Types of vaccine
        
            </button></a> <a href="prevention.html"><button class="s" style="padding: 20px;">Preventions</button></a> <a href="bye.html"> <button class="d" style="padding: 20px;">Log out ></button></a>
        </div>
    </center>
    <center>
    <div class="jo" style="width: 90%;padding: 20px;">
    <center><h1>Vaccine</h1></center>
        <p><font color="blue"> A COVID‑19 vaccine is a vaccine intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2), the virus that causes coronavirus disease 2019 (COVID‑19). Prior to the COVID‑19 pandemic, an established body of knowledge existed about the structure and function of coronaviruses causing diseases like severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). This knowledge accelerated the development of various vaccine technologies during early 2020. The initial focus of SARS-CoV-2 vaccines was on preventing symptomatic, often severe illness. On 10 January 2020, the SARS-CoV-2 genetic sequence data was shared through GISAID, and by 19 March, the global pharmaceutical industry announced a major commitment to address COVID-19. The COVID‑19 vaccines are widely credited for their role in reducing the spread, severity, and death caused by COVID-19. <br>

In Phase III trials, several COVID‑19 vaccines have demonstrated efficacy as high as 95% in preventing symptomatic COVID‑19 infections. Twenty vaccines are authorized by at least one national regulatory authority for public use: two RNA vaccines (Pfizer–BioNTech and Moderna), nine conventional inactivated vaccines (BBIBP-CorV, Chinese Academy of Medical Sciences, CoronaVac, Covaxin, CoviVac, COVIran Barakat, Minhai-Kangtai, QazVac, and WIBP-CorV), five viral vector vaccines (Sputnik Light, Sputnik V, Oxford–AstraZeneca, Convidecia, and Janssen), and four protein subunit vaccines (Abdala, EpiVacCorona, MVC-COV1901, Soberana 02, and ZF2001). In total, 330 vaccine candidates are in various stages of development, with 102 in clinical research, including 30 in Phase I trials, 30 in Phase I–II trials, 25 in Phase III trials, and 8 in Phase IV development. <br>

Many countries have implemented phased distribution plans that prioritize those at highest risk of complications, such as the elderly, and those at high risk of exposure and transmission, such as healthcare workers.[7] Single dose interim use is under consideration to extend vaccination to as many people as possible until vaccine availability improves. <br>

As of 31 July 2021, 4.18 billion doses of COVID‑19 vaccine have been administered worldwide based on official reports from national public health agencies.[12] AstraZeneca anticipates producing 3 billion doses in 2021, Pfizer–BioNTech 1.3 billion doses, and Sputnik V, Sinopharm, Sinovac, and Janssen 1 billion doses each. Moderna targets producing 600 million doses and Convidecia 500 million doses in 2021. By December 2020, more than 10 billion vaccine doses had been preordered by countries, with about half of the doses purchased by high-income countries comprising 14% of the world's population.</font> <br></p>

<img src="data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wCEAAoHCBQUFBUUFRUYGBgaGh0aGxoaGhsbGR0bGxwZGxobGxghIy4kGx0qHxoYJTooLS4xNDQ0GiM6PzoyPi01NDEBCwsLEA8QHRISHzUrISozMzMzMzMxMzMxMzUzMzUxMTMzMzMzMzEzMzMzMzMxNTMzMzM+PDEzMzMzMzM1PjMzM//AABEIAKgBLAMBIgACEQEDEQH/xAAbAAEAAgMBAQAAAAAAAAAAAAAABQYBAwQCB//EAEsQAAIBAgQCBgUJBAcFCQAAAAECAwARBAUSITFBBhMiMlFxYYGRobEUI0JSYnKSstIzgsHRBxVTc5PC8BY0VKLxJCU1Q2N0g7PD/8QAGQEBAAMBAQAAAAAAAAAAAAAAAAECAwQF/8QAJxEBAQACAQMEAQQDAAAAAAAAAAECEQMSITETMkFRFARhcZEiwdH/2gAMAwEAAhEDEQA/APoFRfSTMmwuHeZFVirILNex1uiHh4ar+qpUV8/weExaIDLDLiB1ZDxOwYbYssG0uSJJeqN1NxbQoIO1u/PKztGOMWHD9I1A+cWzfKWw9kKkqQ4RWdGIZblkvp1W1qb2NdGFz1JIjMscmjkzBAGs7xsFGu9wy8DbvC16r5w+K1g/JIHsYyG6nRqd43klcsx1KflCQ72BFxfcVoxmExICyQYcgrBKFjMYTSXlgYxsqkC9xKdSkX486zmWUW1F9NKyaxXQzKUpQKUpQKUpQKUFUjpLmk8brplZdSo1hYAahew9vO5rPPkmPlbHHa70qgZfmkz96Vz+8R8Ku+TYfrANZc3+2/8AA1n+RPpPp10UrznmGSNbrrBA/tJP1VXcoxLSPZnc7/2j/qp+RPo9OrJSuDO4+rQFC4P945+LVz9H8TJIh1tq5gniN2Fr8xt58d+FrY80yui4WJelKVsoUpSgUpSgUpSgUpSgUpSgUpSgUpSgUpSgVpMHHtP+I/6FbqUS0nD/AG35/S8ayIN76n437xtxva3hW2lRo2UpSpQUpSgUpSgUpSgCvnXTM9uP+6j/ACCvotUTpphELM2jEArYatPzFzuCGsebWtcbiwArn55uSr4XujMl5V9OyKRAFuyjzIFfGoUQELZ2PgCFPwNWTAYOWwMeGc+BuT8AK5Gq99KcXHpI6xOH1h/Oqn0cmXrO8OPiKj8wy3FSbthyPUT7bmuDCZdKna6ljY/V+PGg+l9ILNHao7o6lo7fZX8z1S8VIXkROpdC2wEQYOeZsOJPE7DkavuU4RY4lC67kAkv3+HBvC2+wtxPMmtuHG3Lamd7ad1KUrtZFKqGc9J5opurVYtNgRdXLdoA8Q4HPwqZyHGSYggMVUfZXf3k1n6uK3RUtSobOsykgkEakMCbdpd/cRWzNcdJFHHIuglhuCrW5cLMKj1MTpqVpXiFyygkWJF7V7rSKlKUqQpSlApSlApSlApSlApSlApSlApSlApSlApSlApSlAqH6T/sL6gO0NiLhuOx3HDvD0qPQRJYnErGupvGwA4k7mw9QJ8gahnxJka7cACAo4WNr7ncnYb7cOFY8uUk0tjO6pYeCSRwwkRDyJUi3sBqVGHm/wCKZj6FxBH/ANdqkvk6KSQrXP23I9l6w2Hj4mFD6Sik+0iuRptwLhZPpP69RB9jFTW2DLJLXTFOD4BJWH4kLV1IsfKNB+4n8qPBEeMUf4F+NqG3Hh8DiGkV5ZiAm4JJDb/VD2a9r+vla9XKq1DZSArOovcASPYeQ1bVMRS6NIvdCQu9rqWNlAtxQkhQOIJHEd3bhykuqrlNu2lKV1s3zPpcrLir2BACjZ0PdVRuAbrw5gVJ9H+kogsTGp3/ALQX9gBrr6ZQB2j0hSwB1dkXAa1je4JJt6eHpqMwcMkagKzL5Qqf+a9648sdWyNZl2a87z8zSh+rUC9+8T/lFSeNz0TrDCqKW2FhIBvtt2wo99c5WRrFpH9UTN7iBW7KoguISR5F0rcbxpGdweI4jcDf/rSY206lgOcwR2jkkAcAXUBzvbkQu4rtgxSSKWTUygXJCN/EV866RvpxpuCOyvI8kUG22+9W/J8+gjw7qxa5X6jfxFXnLfCOmJODMIpCVRiSOICPtb1V7w2KjkvobVpNjxBB8jVU6M5tGskzMSAQxHZJ9w3qX6MkFZGW9me4JBAO3K43q2HJbdFxkibpSlbsylKUClKUClKUClKUClKUClKUClKUClKUClKUEJ0kYjq/Ahx74648t4V39IIy3VgBjs/BSecfgNq5cuhYDdH/AAP/ACri5PdWmPhYcggR2fUoNgLV09IsMiwsVUC3hWrIOwXZlcXAHcf9NdeduHhdQHvbb5t/01kuqmQRrJKqPwYH0cK6+kuBSHTovvXJ0fgdMQjPHIFW+5R7fCpHpkWfqurSRtzeyPtwt9Gp+UfCt4ZyTapTEE9W/oRj6wCQfO9RuGw0gO8bg+lHH8Kl5QvVSXvfq2+g/wBU+ipiEwa4s1nMcTsvHYX8LsBf312muPNIDJEyC1yV48NmB8D4V3Ze1nPKtwsWFyTuf9edd+Myzq4y+okitmByaRhpDJ+Jv01O43KZGjZDoFxa+pv0VhM8dd1+mqphsKzxtICLLxB48Aa58PKdQtyqx4DJJEikj1IS997ttcWG2mo1shkiN2ZD5Fv01W549tHTVdzzCa5AAvEDe52uTta/2b7eNe4sLpAHVIfT1RPvJNTskF5FU7BgvA34s3oFeM4wqxaLXN73v6Knp3No3fCEfAgg2VLn60bIBf7QI+FXHIUVYI0Ug6RY24X8iTa/GoTMoOq0731C/C1dmUudcY8bg+Wlmt7QKvhqXRbtP0pSt1ClKUClKUClKUClKUClKUClKUClKUClKUClKUGuZbg+hWPvSteCk3rbKey392/5kqgHp/Grt1OGmxCJ35F7oA4kbHbY7nTwrh5fdWuPh9cwbXFZxJqoZ/05hwLRxCN58Q6hlijG9je2o72vY2ABO1ack6fpipHw74eTD4oKWWGTYuQpbSrEAhrDgVG3jWS60A711KNqq3R3pZBi8NLigGjWIuHV7al0LrJ28R8CK4X/AKR4lwUeMbDSBJJTCi6l1Gykl/DTcMvjdTQT+YtUO7/Ny/cb8pqM6T9M1hxcuEGGmlaMKxMYDdllVr6eIA1AVjJM6hxeHmeInZGDKwsynSSLj08iNuPgalC2msVk14fgfI/A135e2sZ5QGQdKIXdyFlESK7HEFLYciPv6Xvcnjy3sbVJQdOYJSqCHEprVmhMkWlZwilrRMWsWIFwG03uPGq/0c6OS9TJg3mRsK6SItkImUPci7X0kKWJ4b+W1SRyqZJsFHjsdAwhN8PGq9XJNIq6FZ9TG5UHgvG+9cDdJYTpVh2GFZA7/KUd0CqpKpGupzJ2rLY9nie1tUJnHTTDsIyI8QQ8C4i4QMEjZmXVJpYkWK72uNxW3IMnwsOMxiLi4mkkVo4YNa64VctJKgS/NjqsBcBajcw6JYiERhMRGunCLhXJRmNldmLoNQAPaHG9QLRlOFjn6uTUSCiMpUixG5U7g+Nd+Z5LHJYMXNuG4HwWqbJM2DhMeHmfXHBEpQIJDHF1io+JChbs4Uttw2vbsms/1xOVxEmHxUmKw+GMMwkZEBdQWOJgDhFWQBAHuACpsL1bqs7bRqLXjsiikUMxclRYbgbeyozCQKsigX2Y+H1H9FQuMzjGLAkrSspnw+OxKoQvzaqsTYdO79FGvvfdze+1eeiWOeSVx1rTRjQVkZQp1tG5dAyqocLZd7bXtV8MrcojKTS40pSu5iUpSgUpSgUpSgUpSgVz47FrEmptyTZV5sxuQB6gSfAAnlXRXOuHWSbSwBVIy1iQN5G0g+YEbj941nyZdOO1sZuo3CYtZNQmdgT3Sjugv9QKhBa+9uLfCuvAYpWd4w5bSAw1Aq4BuCrKwDbWBDEbhudrnhijUSs8THXrZEtZgiJtK4+2XunMdw22N/cGCSNy41hyoQuXdm0gkgdssuxJPDma5ceSzLdaXHcTVK4UZ/oyqf7xAT+JCgH4a2iSQcY1YfYftH1OFA/FXRObGqdFdNK5zibd6ORf/jZgPN01KPbWYcZG5skiMeYDAkeYvcVpM8b4quq3MwAJJAAFyTsABxJPIVFtmkl2YQnq1uCzEh2I4iOPT2iOYJB5d4FRtxEuuZY+sVETtyuSBpCgMBvwO6m54XB30kV5xjSSyL1EBZI7C2tYyAOWkjY2+iSCLjUFvesOTlsuovjh27veZJ1uHlVGtrw8gVgeGvQAwPrBr5t0O6VQZfC+GxMbxyI7EgLcvfcfvbAXO1gu9fRtLJFKrRvGAshVX07K0iFQGQspAvawJsNNasviRypZFYjgSASPInhWGd6rtaduyr4/GjLM6OPxETNh8REESRRq0NojU/vDQRbjpe4vwrziczXN83wcmDR+rw1mkmK6bgNq0nnY20gHc6m2sL19Yw8SshVlDKeIIBB8wapuc9LvkmOiwPyErHJJGkcoYKja9GtlTRY6Gex35cqosoHTPAYjDY2fCYcfN5kYyBuO2ZLsARw7Ra4+q4qw/wBLOXphstwMCd2OZEB8dMb3Y+km5PpJqdzfpi0eLODwuDfFTxrrcBwiqCFOzFTc2ZfAdoDc7VMdEukkWYwu4jKOjaJI3sSj28bC4472B2OwoPm+eZxDhc+xckzFV6lE2BY6jHCQLD0A156FxOxzDF6Ckc4YopFiR221W9Y34XJ8K+mZqg3JAJ8bCoKX9nL9xvympRVgNa5e6fI/A1sNaZzZW+635TXfn7axnl46PDZa2dL8vklfAOiauqxcbueyCqBXDHc7i5XYVF5ZmyRXDBrqCSBbuhC+q1+BI0feI86nRnqvptE5GlXY9jsayygMNVyQVa+m9rc6865Tbs9HPW9dlXwfROYY5Rq/7JHO2MDMiLIZnv8ANq4bU6Am5LAbbb7EWPpBwNeG6TIkayNDKFcXXuEsvVySgizbHTGdjvdl9No3Ns+jkIVFY3JAJ0gdlYmNwTcEdaota91bwp1z7T+PyXxErkHH1ConPsVjBisZFh5bsMIksSuECo5kdG0sQL9lCRrJGpt9uHXgcyjg3cnu6tgWNgVXgPS6j/pUnJm0RbYOe0VUhSQzKxVlU8CQVbjbuk7gXpcpvSnp5al1dIrohj5p8NJI5kaMyHqHlEYlaMKt2bq+wRr16SOIA47GtMZ+dH3/API9S+Iz6ADQSwJAsCjKdygtYjZu2NjY7Ntsag8BOsjh03Uttw+q/gavx5S5SIz4spOqy6TFKUr0XKUpSgUpSgUpSgUpWCbbmgzUDnkzRyxkbJKhjJ+2hLovrVpT+5WvHdLI0JEalz430p6juT7KhMV0kkkBSSONkNroQ3IgizarhgQCCOBAIrn5M8bOna+ONnduikxWDZZlw/WxtI6q2tB+3dWZNLsDr6wDTa4INtjVyGcRcJI5EPPUjFR5uAyf81VbL84wgKM4m1J3Osd5lTYi6amOk2JGoKCQdzVggznDv3ZU9Z0n2NassOPGzvVrlZ8OmJ8JNvHIjelWB96k16fKuaO3xHtFap8JFLYvGj+BZVb2E8K0jLFXeN5Yz4rIxHqR9Sj1CpvBfinXG3qZ07rBvjWnF459JE0KyKB3XQOD6O0DxrcPlC8JVceEkd2P76kW/DXDmeYyqqo8aKXYKGSQsAfonSygizaT6qplx5Y+YtMpUVicKkaJIOzrs9kXbtFmjCLa1gqPIEPBnjHCprCvIqgWjA5IFe6+gy6yWPi2jckmonMMXqldgDaJ1ZkXchV+REkLxOhQrWG9ibcasUWYxyDuo48V0t7xWaXNipmeOQNtZDYay43ePmVUjh4V4yocK24xozHJoUr82bglrftI7WB4c615YeFSj5WvBcK+b/0n/wDiWSf+4/8A1w9fSMHwpPUJfKun2FOAnbMcNizFPOoj6kIsjSMNIuoOwA0qSSDY2tuwFWr+jfo7Jg8K7Tm+Incyyb3KkjZSebC5J9LEb2vVojroHA0EBmvA1ASfs5fuN+U1Yc1GxqvSfs5fuN+U1KKsBrmxptG33W/I1RrZhOhCuEZrJcFHjAdzYrrUyBgAHYnSNgNjfbGIzcMpUpbvgurI6WjBEjadSvpG4uUG/mL9V5MbjYzmNlbskw0chGtFY2C7gHYMHAPo1AG3oqxNk+HBUiJAQbiyjY6i424bMSw8CSRavn8GcTwyAaUTgbSI8bWa9jod1bex5cjVszLNZ0iMgKEgAgFGtvb7dc84995G05cpNbqTTJMNa3UpY+jlpZbegaXcW4DUfGovP8BELuI1DXY3AsbtpuduZ0LfyFR+S9JsTLJobqgNJOyNfa3jJXOc4mnZkfqxYngjcjbm9ROL9j1svupjKsJHIw1xq11W+oA3C6tIIPG2pvbUp/VUANhGoGw25WIOx4ruAduJ3qlT42SPExKJCAUW4UlR3mHC/Gu7pJjJY+rMcjre9+2x8LcSat6Xmk5rO27/AGtM2VQBCBEoA02AUWGju2HK1VzCIFk0gWAbb8L1wSZlN8mifrX1MzBjrbcC9tr28K7cAvaVrsSSCbuxHdbkTarcfFrKVXLkys1bUvSlK7WBSlKBSlKBSlKBWrEwiRHjbuspU242IsbVtpQVZ+hy/RlYeaA/AiuGbolMO66N6yp9lre+rvSsrw434X66+czZFiU4xMfu2f8AKSaj5YmTZ1ZfvAj419WoRfY7iqXgnxU9b5RE7KbqxU+Kkg+0VIw57iU4SsfvWf8AMCavM+UwP3okPpCgH2ixqPm6K4ZuAdPutf8ANeqejnPFT1S+UNB0umHfRG8rqfbcj3V34PP455Y1eMoLqO9cX6yNieA2Co2/nUHneU9TIETW4IvcrtvfYEcTWvC5LiX7SRsPvWUH0WYi4NVuWffGp1j5WXO42+Wdfh5FjeMEOGTrEdALFSoYHUbINjvoj5qDUs6lwpmw0UhAFyjdrVz0o62Av9uqfi8FjiBqjNgQ3Y3ckbrqYOxNtvA3AJua1jOsZEbOzjlaRP4sL++oxknulLv4WvEaBHLpSROwLq5vb5xLabOyePdPhflUQ2ZvAWvuGjJjFv8AzFIXR4m+pD7axgc4knjn6wKNKLbSCO9InG5P1akMDAkmjWobQwZb8mHA1lyY7n+Nb/p88cct8k3PmNuF6RyJi4oHkQoNMTjshmmZS2oAb6Q2lfC7VvwOYYmWNMWZ41R5NPUsoUBdZTT1ne63bhwJ2tU1hsnw7IymNSGbWeNyxYNq1d4HUAeNef6hwol64QqH1ar721c2030hvTa9ZzHLfl1Zc/DfGOrqTxL/AD/f3+yHwGOxMiLi+viRGk09S6hVC6ymnrO91u3lflWg9JcQjRMe3GGxBlAAuI45QgK2F7qGBI5gGrCmQ4YS9d1S69Wq+9tX19N9Or02vXRBlcKG6oAQHANydpGDPsTzYXp05fZf1HDu3p3PrU7f9/lRMRnM0ixaXYhxMxKRoxISUqhttYabb+VdUYJhkve/Vm9xY3073UcD6Kks0yPDBFURKFQMFF27Oo6mtvzJvUdEoWORQLARkAegKQBU4Y2eap+q5uLPGTjmu9+P9pQY6MvrdSDrLnb6ZjEYPqS4t6a5JIcO8kMdxp0olj3gkep3a/Mu/wAnUjmAfGu/+uEbaWIH1b+0VqbD4SR1k7SEKy2BFu0UJO4vfsDn41rpw7YjwCjVIuvYSyaVYi5X5uFAPEx67jkXJ51oXIVVZQunVqWEMq6C0r2aSVjGylhd7kHlG3jXYMpXjHPb0HaufEYbFdYiBlcIrSbNwJ+bXj4hpPZUJQmVYJsPi3jck6AQGPFlNijH0kEA8tQYcq04BrSOT4n4125rhpJJJJGfQ8arHbUATt1hPg2zi1+Ha8TUZgcoxMmp1cgC1zo1nUQGAK613AIvvxrbDPtIzy1O5m2LjTERszqNKpcEi/eY/C3trOdZzFME0uOyT77eFWHAukYswOo8SdI4feC+nYauNSMOIV76WvY2I3BB47g7jYg1rJvc35VmUvhR2zGMwxx6t1Yk7bb3/nU5kmKEhGjcA7nkLKeJ8eG1WG9CatjhZfKdsUpStVSlKUClKUClKUClKUClKUClKUClKUClKUCsMLix3HhWaUENmOEjQP1aKmpBfSAL2kS1wPM+2vOWggipLE4dXLBr7QuwszLuGT6pF6oeOZlawkkHlJJ+quHk91a4+H1vAHs16kO9VHoP85qDvKdr/tpduH26l+lGECYd2R5VYWsRNLf89ZrphDW5Tsa+RHEy2/3jEf48v66u00X/AGBZBJLr0A6uulvfx79NI2681QkGoJIj1c33G/Ka48qDO6q0kjfekkP+ap1stjEcuzfs5D33+ofTQUuDpbiR+0jgl8tcZ9Zu49iiu+LpXhztJhpU8WTRIo9jBz+CrS2GjbiiHzUH4iuWXJcM3GFP3Rp/Lauj0L9qdc+kbBnWXykBcT1bHYLIGjJPgNYFzW+LDESyv8oAQLGhIJYn9owCoN2Y6jYDc2rzL0VwzbAOvk5P5r1pwnRZYGL4aXq2PEmONr+gkAVX0cjqhj8PiTHL2QUJLWJ+dI4bgAgGw4Bj/Cs5bj0iQIVZG1Oe9oY3Y2Oh7E7W5V2qcavEQOPQXjb3givLZnINpcLKBz0aZF9x4Vp6ciuU22SZqoBLsCACbSJYkDfZhVeaTq5GN9JvpuHMY7N9W3GS7lzpXbfc8hMacHICujRfvALJF+Jl0g+2tn9TYWS7IN/rJIT5nckXJ4nnUzBlcK4MPnEqntHWgBd9ShZFjQFnksvZAA+ibsasw8agk6NRBjd2ZCpUxkLvqIL6nUAkHSoI8Ba9iQepcjhQgxh4rcBE7on+Gp0H1qavjueV8Z27pOsE+uuVIJV4S6x/6iKW/EmgD8Jraskg70f4GDe3UF916ttOm6lavlC8zp+8CvsJtf1VtBqdhSlKlBSlKBSlKBSlKBSlKBSlQGY5ti42bThNaAmzh9V1HMqBceVRbpMifpVAfpriD3UiA8nPv1Vr/wBs8V4Rfgb9VU64dNfQ6VR8J03cLaSIOb95W0bfdIO/HnXdH03h+lFIPLS3xIqeuJ6atUC3eT+5ce0rXzjMu8PKrx0czuLEyuI7hhC/ZYWPeXwJBG44GqRIhfjxFx765OS7yq88Lb/R63bYfYPxWrL0q/3Z71U+h8widyx03Wwv5gn4CpnPcxjkgkjDXJG3nWfysoTnY1fy3/dy/cFUJoyNrVcXxSHBCLUNRTx5ipEVkbfOL/rlVmv81L/dP+RqquVOEIN+FT3ykdVKxPFH9mhr+6iI7KUFK9FiUpSgUpSgwRfjXl41O5UE+kA17pQYAtWaUoFKUoFazCvhY+I7J9osa2UoNXVsODnyYBh/Bj7a9rq528xf4cvaa9UqNBSlKkKUpQKUpQKUpQKUpQRGL6N4WS5MYUnmhKe4be6oaboMv0JmH3kDfAilKrcIbaP9hn/t1/Af1Vg9B5P7ZfwH9VKVHRFuqsx9DJ0IaPEBGHBl1ow5bMpuNtvXWU6KY0G/ylL+Onc+fZ3NKVS8cOqvadGcbzxKAehb+7SK3jopOeONPkIkt7zSlW9LH6Oqsf7ISc8a/wDhJ/Osjoe//GP/AIafzpSnpY/R1VkdEpBwxZ9cQ/XUpleTmMDrJnkPkETY3HZFztt9Kx8KUqZxY/RupelKVdUpSlApSlApSlApSlApSlApSlApSlApSlB//9k=" alt="">
</div>
</body>
</center>
</html>